Transcriptional correlates of the pathological phenotype in a Huntington’s disease mouse model

被引:0
|
作者
Andrea Gallardo-Orihuela
Irati Hervás-Corpión
Carmen Hierro-Bujalance
Daniel Sanchez-Sotano
Gema Jiménez-Gómez
Francisco Mora-López
Antonio Campos-Caro
Monica Garcia-Alloza
Luis M. Valor
机构
[1] Instituto de Investigación e Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA),Área de Fisiología, Facultad de Medicina
[2] Unidad de Investigación,undefined
[3] Hospital Universitario Puerta del Mar,undefined
[4] Av. Ana de Viya 21,undefined
[5] Universidad de Cádiz,undefined
[6] Plaza Fragela,undefined
[7] Servicio de Inmunología,undefined
[8] Hospital Universitario Puerta del Mar,undefined
[9] Av. Ana de Viya 21,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Huntington disease (HD) is a fatal neurodegenerative disorder without a cure that is caused by an aberrant expansion of CAG repeats in exon 1 of the huntingtin (HTT) gene. Although a negative correlation between the number of CAG repeats and the age of disease onset is established, additional factors may contribute to the high heterogeneity of the complex manifestation of symptoms among patients. This variability is also observed in mouse models, even under controlled genetic and environmental conditions. To better understand this phenomenon, we analysed the R6/1 strain in search of potential correlates between pathological motor/cognitive phenotypical traits and transcriptional alterations. HD-related genes (e.g., Penk, Plk5, Itpka), despite being downregulated across the examined brain areas (the prefrontal cortex, striatum, hippocampus and cerebellum), exhibited tissue-specific correlations with particular phenotypical traits that were attributable to the contribution of the brain region to that trait (e.g., striatum and rotarod performance, cerebellum and feet clasping). Focusing on the striatum, we determined that the transcriptional dysregulation associated with HD was partially exacerbated in mice that showed poor overall phenotypical scores, especially in genes with relevant roles in striatal functioning (e.g., Pde10a, Drd1, Drd2, Ppp1r1b). However, we also observed transcripts associated with relatively better outcomes, such as Nfya (CCAAT-binding transcription factor NF-Y subunit A) plus others related to neuronal development, apoptosis and differentiation. In this study, we demonstrated that altered brain transcription can be related to the manifestation of HD-like symptoms in mouse models and that this can be extrapolated to the highly heterogeneous population of HD patients.
引用
收藏
相关论文
共 50 条
  • [31] Behavioural assessment of a mouse genetic model of Huntington's disease
    Johnston, HM
    Ennis, M
    Myers, RM
    Shelbourne, PF
    BRAIN RESEARCH, 1998, 809 (01) : A26 - A26
  • [32] Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease
    Schroeder, Analyne M.
    Bin Wang, Huei
    Park, Saemi
    Jordan, Maria C.
    Gao, Fuying
    Coppola, Giovanni
    Fishbein, Michael C.
    Roos, Kenneth P.
    Ghiani, Cristina A.
    Colwell, Christopher S.
    PLOS ONE, 2016, 11 (01):
  • [33] Imaging brain metabolism in a mouse model of Huntington's disease
    Farzana, Farheen
    McConville, Malcolm
    Hannan, Anthony
    Hatters, Danny
    Boughton, Berin
    PROTEIN SCIENCE, 2021, 30 : 27 - 27
  • [34] Altered dopaminergic function in a mouse model of Huntington's disease
    Dallérac, GM
    Milner, AJ
    Cummings, DM
    Vatsavayai, SC
    Hirst, MC
    Murphy, KPSJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [35] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6
  • [36] ACMSD Provides Neuroprotection in a Mouse Model of Huntington's Disease
    Fink, K. D.
    Deng, P.
    Cameron, D.
    Brundin, L.
    Manfredsson, F. P.
    CELL TRANSPLANTATION, 2021, 30 : 5 - 6
  • [37] Therapeutic potential of erythropoietin in a mouse model of huntington's disease
    Rolfes, S.
    Boettcher, C.
    Priller, J.
    HUMAN GENE THERAPY, 2014, 25 (11) : A107 - A107
  • [38] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [39] Striatal transplantation in a transgenic mouse model of Huntington's disease
    Dunnett, SB
    Carter, RJ
    Watts, C
    Torres, EM
    Mahal, A
    Mangiarini, L
    Bates, G
    Morton, AJ
    EXPERIMENTAL NEUROLOGY, 1998, 154 (01) : 31 - 40
  • [40] Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease
    Diguet, E
    Rouland, R
    Tison, F
    ANNALS OF NEUROLOGY, 2003, 54 (06) : 841 - 842